Post-market safety data for underrepresented populations in clinical trials
Introduction Regulatory agencies require sponsors to collect and provide data on the safety and efficacy of drugs that they have obtained from clinical trials. In addition to age, gender, and racial subgroups, these trials should also incorporate data on patient populations that are historically underrepresented in clinical research. Indeed, information from a diverse patient population …
Post-market safety data for underrepresented populations in clinical trials Read More »